Łukasz Zapała
MD, PhD, FEBU
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Purpose Cancer diseases and type II diabetes mellitus (DM2) are today among the major health problems, particularly in developed countries. DM2 has been historically suggested to protect against the development of prostate cancer (PCa). This study aimed to explore the mechanisms of this relation and assess its impact on treatment and prognosis for patients with PCa. Methods The consecutive literature search was performed using PubMed, Cochrane, and Google Scholar for papers published between 2015 and 2025. Results DM2 might reduce the risk of primary PCa development with a size effect depending on the duration of DM2. Patients with type 2 diabetes often exhibit low levels of testosterone and SHBG, which has been speculated to constitute a protective effect against PCa development. On the other hand, peripheral insulin resistance might be a protective factor, given its proliferation-promoting properties. What remains, however, the backbone element of the DM–PCa prevalence relation is metformin, which has been described to modulate PCa development through activation of AMPK kinase, reducing the c-MYC oncogene and disrupting the action of androgen receptors. Finally, DM constitutes a well-known predictor of worse surgical outcomes as well as radiotherapy toxicity. Conclusion DM is associated with a modestly lower incidence of prostate cancer, likely mediated by hormonal cross-talk and metabolic changes. Metformin may confer additional protection in a wide range of molecular mechanisms. Nevertheless, diabetes worsens treatment course—raising surgical morbidity and radiotherapy toxicity—necessitating tight metabolic control and thoughtful anti-diabetic drug selection.
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
We aimed to determine whether berbamine (BBM) would have an effect on retinyl acetate (RA)-induced cystometric and biochemical parameters, characteristic of bladder overactivity. BBM exhibits anti-inflammatory, anti-oxidant, and muscle-relaxant effects which could counteract pathophysiological mechanisms observed in overactive bladder (OAB) syndrome. The cohort of 60 rats was divided into 4 groups: I—control, II—RA group, III—BBM, and IV—group with the combination of RA + BBM. The cystometry, BBF, cardiovascular parameters and diuresis, the analysis of the cFos, and biochemical biomarker levels were analyzed 48 h after completion of BRB administration. The examined substance turned out to reverse the cystometric changes and c-Fos expression changes induced by RA when compared to the control group. There were no significant changes observed in the analyzed groups of animals MAP, HR, BBF, or UP. Importantly, BBM also turned out to reduce the level of OAB biomarkers present in urine (NGF, BDNF), urothelium (TRPV1, SNAP29, ATP, CGRP, or OCT-3), bladder detrusor muscle (VAChT, Rho kinase) as well as to reduce the exponents of oxidative stress (3-nitrotyrosine, malondialdehyde). The multifactorial explanation of the successful alleviation of the RA-induced detrusor overactivity makes the concept of incorporation of BBM in the OAB treatment promising for the future research.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (10)
Rafał Pęksa
Medical University of Gdansk
Piotr Dobrowolski
Professor (Associate)
Maria Curie-Skłodowska University
Andrzej Wróbel
Medical University of Lublin
Ewa Urbanska
Full Professor, Head of Department
Medical University of Lublin
Artur Wdowiak
head / associate profesor
Medical University of Lublin
Michał Kunc
Pathologist
Medical University of Gdansk
Tomasz Kluz
Professor
Rzeszów University
Marcin Misiek
-
Ilona Sadok
Assistant Professor
John Paul II Catholic University of Lublin
Jakub Kwiatkowski
Medical University of Warsaw
Make your next move.
Prepare your application
Review drafts before you send them.